Nanosphere Inc (NSPH) 1.43 $NSPH
HemoSonics Names William P. Moffitt as Chairman of the Board of Managers
PR Newswire - Thu Jul 31, 9:23AM CDT
HemoSonics, a medical device company developing a novel point-of-care diagnostic to measure coagulation, announced today that William P. (Bill) Moffitt joined the Company as the new Chairman of the Board of Managers. Moffitt has 40 years of experience in the medical device and diagnostic industries and has spent the last 25 years developing novel technologies into products and solutions that have helped shape the industry.
Nanosphere to Release Second Quarter Results and Host Investor Conference Call on Wednesday, August 6, 2014
GlobeNewswire - Wed Jul 23, 7:26AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will report its results for the second quarter of 2014 on Wednesday, August 6, 2014. The company will also hold a live investor conference call and webcast at 5:00pm Eastern/2:00pm Pacific.
Biotechnology Stocks Technical Review -- Research on Medivation, Idenix Pharma, Nanosphere, and Progenics Pharma
PR Newswire - Fri Jul 11, 7:00AM CDT
On Thursday, July 10, 2014, the NASDAQ Composite ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the session at 16,915.07, down 0.42% and the S&P 500 closed at 1,964.68, down 0.41%. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.02% lower at 711.88, while the index has gained 9.23% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Nanosphere Inc. (NASDAQ: NSPH) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Free technical research on MDVN, IDIX, NSPH and PGNX can be downloaded upon signing up at:
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Stock to Watch: Nanosphere Down 5.2% (NSPH)
Comtex SmarTrend(R) - Thu Jun 26, 11:39AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing low-priced stocks, down 5.2% to $1.57 on 1.1x average daily volume. Nanosphere has traded 965,000 shares thus far today, vs. average volume of 856,000 shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -0.5%) and underperformed the S&P 500 (-5.2% to the S&P's -0.4%) during today's trading.
New Patents, Clinical Trial Updates, New Agreements, and FDA Approvals - Analyst Notes on Agile Therapeutics, Vanda, Galena, Nanosphere and Rockwell
PR Newswire - Thu Jun 26, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agile Therapeutics, Inc. (NASDAQ: AGRX), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Galena Biopharma, Inc. (NASDAQ: GALE), Nanosphere, Inc. (NASDAQ: NSPH) and Rockwell Medical Technologies Inc. (NASDAQ: RMTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4128-100free.
Why Nanosphere (NSPH) Stock Is Surging Today
at The Street - Wed Jun 25, 1:13PM CDT
Nanosphere (NSPH) surged Wednesday after the molecular diagnostics company announced it has received FDA clearance for the bacterial portion of its Verigene Enteric Pathogens Nucleic Acid Test.
Nasdaq stocks posting largest volume increases
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Verigene(R) Enteric Pathogens Test Receives FDA Clearance
GlobeNewswire - Tue Jun 24, 5:00PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing the practice of medicine through targeted molecular diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the bacterial portion of its Verigene(R) Enteric Pathogens Nucleic Acid Test (EP). Clinical studies for the full panel, including two additional viral targets, have been completed and the Company expects clearance of the full EP panel.
Nanosphere (NSPH) Jumps: Stock Rises 14.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 8:39AM CDT
Nanosphere, Inc. (NSPH) was a big mover last session, as its shares rose nearly 15% on the day.
Hot Stock: Nanosphere, Shares Gain 16.8% (NSPH)
Comtex SmarTrend(R) - Mon Jun 23, 10:39AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's best performing low-priced stocks, up 16.8% to $1.60 on 9.7x average daily volume. Nanosphere has traded 5.9 million shares thus far today, vs. average volume of 615,000 shares per day. The stock has outperformed the Dow (16.8% to the Dow's -0.3%) and outperformed the S&P 500 (16.8% to the S&P's -0.2%) during today's trading.
Nanosphere Signs Molecular Diagnostic Supply Agreement With HealthTrust
GlobeNewswire - Mon Jun 23, 7:01AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it has been selected by HealthTrust as a provider of multi-target molecular diagnostic tests for the nearly 1,400 acute care facilities that are part of the HealthTrust membership.
Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
PR Newswire - Tue Jun 10, 7:00AM CDT
The US markets on Monday, June 9, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,943.10, up 0.11% and the NASDAQ Composite closed at 4,336.24, up 0.34%. The S&P 500 finished the session 0.09% higher at 1,951.27. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 691.34, down 0.48%, whereas the index has advanced 3.44% in the last one month. Investor-Edge has initiated coverage on the following equities: Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), Alkermes PLC (NASDAQ: ALKS), Nanosphere Inc. (NASDAQ: NSPH) and Organovo Holdings Inc. (NYSE MKT: ONVO). Free technical research on NAVB, ALKS, NSPH and ONVO can be downloaded upon signing up at:
Twelve Studies Presented at ASM 2014 Highlight New Performance and Clinical Outcome Data Using Select Verigene Infectious Disease Tests
GlobeNewswire - Wed May 21, 7:15AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that twelve studies evaluating the performance and clinical impact of select Verigene(R) multiplex infectious disease tests have been presented at the 114 General Meeting of the American Society for Microbiology (asm2014), held this week in Boston, Massachusetts.
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nanosphere signs USD30m purchase deal with Aspire Capital
M2 - Wed Mar 19, 8:23AM CDT
Molecular diagnostics company Nanosphere (NasdaqGM:NSPH) reported on Tuesday the launch of a USD30m purchase agreement with Aspire Capital Fund.
Nanosphere Enters Into $30 Million Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Tue Mar 18, 4:00PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced it has entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC ("Aspire Capital"
, whereby Nanosphere has the right to sell up to $30 million of shares of its common stock to Aspire Capital under certain conditions from time to time. Aspire Capital is an existing Nanosphere shareholder, having invested in the Company's most recent underwritten public offering in September 2013.
Nanosphere to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:59AM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that an overview of the company's business and commercial strategy will be given by Roger Moody, Chief Financial Officer, at the 26 Annual ROTH Conference, being held at the Ritz Carlton in Dana Point, California from March 9-12, 2014.
HemoSonics Names William P. Moffitt as Chairman of the Board of Managers
PR Newswire - Thu Jul 31, 9:23AM CDT
HemoSonics, a medical device company developing a novel point-of-care diagnostic to measure coagulation, announced today that William P. (Bill) Moffitt joined the Company as the new Chairman of the Board of Managers. Moffitt has 40 years of experience in the medical device and diagnostic industries and has spent the last 25 years developing novel technologies into products and solutions that have helped shape the industry.
Nanosphere to Release Second Quarter Results and Host Investor Conference Call on Wednesday, August 6, 2014
GlobeNewswire - Wed Jul 23, 7:26AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will report its results for the second quarter of 2014 on Wednesday, August 6, 2014. The company will also hold a live investor conference call and webcast at 5:00pm Eastern/2:00pm Pacific.
Biotechnology Stocks Technical Review -- Research on Medivation, Idenix Pharma, Nanosphere, and Progenics Pharma
PR Newswire - Fri Jul 11, 7:00AM CDT
On Thursday, July 10, 2014, the NASDAQ Composite ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the session at 16,915.07, down 0.42% and the S&P 500 closed at 1,964.68, down 0.41%. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.02% lower at 711.88, while the index has gained 9.23% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Nanosphere Inc. (NASDAQ: NSPH) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Free technical research on MDVN, IDIX, NSPH and PGNX can be downloaded upon signing up at:
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Stock to Watch: Nanosphere Down 5.2% (NSPH)
Comtex SmarTrend(R) - Thu Jun 26, 11:39AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing low-priced stocks, down 5.2% to $1.57 on 1.1x average daily volume. Nanosphere has traded 965,000 shares thus far today, vs. average volume of 856,000 shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -0.5%) and underperformed the S&P 500 (-5.2% to the S&P's -0.4%) during today's trading.
New Patents, Clinical Trial Updates, New Agreements, and FDA Approvals - Analyst Notes on Agile Therapeutics, Vanda, Galena, Nanosphere and Rockwell
PR Newswire - Thu Jun 26, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agile Therapeutics, Inc. (NASDAQ: AGRX), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Galena Biopharma, Inc. (NASDAQ: GALE), Nanosphere, Inc. (NASDAQ: NSPH) and Rockwell Medical Technologies Inc. (NASDAQ: RMTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4128-100free.
Why Nanosphere (NSPH) Stock Is Surging Today
at The Street - Wed Jun 25, 1:13PM CDT
Nanosphere (NSPH) surged Wednesday after the molecular diagnostics company announced it has received FDA clearance for the bacterial portion of its Verigene Enteric Pathogens Nucleic Acid Test.
Nasdaq stocks posting largest volume increases
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Verigene(R) Enteric Pathogens Test Receives FDA Clearance
GlobeNewswire - Tue Jun 24, 5:00PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing the practice of medicine through targeted molecular diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the bacterial portion of its Verigene(R) Enteric Pathogens Nucleic Acid Test (EP). Clinical studies for the full panel, including two additional viral targets, have been completed and the Company expects clearance of the full EP panel.
Nanosphere (NSPH) Jumps: Stock Rises 14.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 8:39AM CDT
Nanosphere, Inc. (NSPH) was a big mover last session, as its shares rose nearly 15% on the day.
Hot Stock: Nanosphere, Shares Gain 16.8% (NSPH)
Comtex SmarTrend(R) - Mon Jun 23, 10:39AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's best performing low-priced stocks, up 16.8% to $1.60 on 9.7x average daily volume. Nanosphere has traded 5.9 million shares thus far today, vs. average volume of 615,000 shares per day. The stock has outperformed the Dow (16.8% to the Dow's -0.3%) and outperformed the S&P 500 (16.8% to the S&P's -0.2%) during today's trading.
Nanosphere Signs Molecular Diagnostic Supply Agreement With HealthTrust
GlobeNewswire - Mon Jun 23, 7:01AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it has been selected by HealthTrust as a provider of multi-target molecular diagnostic tests for the nearly 1,400 acute care facilities that are part of the HealthTrust membership.
Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
PR Newswire - Tue Jun 10, 7:00AM CDT
The US markets on Monday, June 9, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,943.10, up 0.11% and the NASDAQ Composite closed at 4,336.24, up 0.34%. The S&P 500 finished the session 0.09% higher at 1,951.27. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 691.34, down 0.48%, whereas the index has advanced 3.44% in the last one month. Investor-Edge has initiated coverage on the following equities: Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), Alkermes PLC (NASDAQ: ALKS), Nanosphere Inc. (NASDAQ: NSPH) and Organovo Holdings Inc. (NYSE MKT: ONVO). Free technical research on NAVB, ALKS, NSPH and ONVO can be downloaded upon signing up at:
Twelve Studies Presented at ASM 2014 Highlight New Performance and Clinical Outcome Data Using Select Verigene Infectious Disease Tests
GlobeNewswire - Wed May 21, 7:15AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that twelve studies evaluating the performance and clinical impact of select Verigene(R) multiplex infectious disease tests have been presented at the 114 General Meeting of the American Society for Microbiology (asm2014), held this week in Boston, Massachusetts.
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nanosphere signs USD30m purchase deal with Aspire Capital
M2 - Wed Mar 19, 8:23AM CDT
Molecular diagnostics company Nanosphere (NasdaqGM:NSPH) reported on Tuesday the launch of a USD30m purchase agreement with Aspire Capital Fund.
Nanosphere Enters Into $30 Million Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Tue Mar 18, 4:00PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced it has entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC ("Aspire Capital"
, whereby Nanosphere has the right to sell up to $30 million of shares of its common stock to Aspire Capital under certain conditions from time to time. Aspire Capital is an existing Nanosphere shareholder, having invested in the Company's most recent underwritten public offering in September 2013. Nanosphere to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:59AM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that an overview of the company's business and commercial strategy will be given by Roger Moody, Chief Financial Officer, at the 26 Annual ROTH Conference, being held at the Ritz Carlton in Dana Point, California from March 9-12, 2014.
